symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
HILS,0.237,0,684778,4171840,0,0.1723-2.65,0.0127,"Hillstream BioPharma, Inc.",USD,0001861657,US4327051011,432705101,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.hillstreambio.com,"Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.",Mr. Randy D. Milby MBA,Healthcare,US,1,908 955 3140,1200 Route 22 East,Bridgewater,NJ,08807,,0,https://financialmodelingprep.com/image-stock/HILS.png,2022-01-12,False,False,False,False,False
